Money page · tirzepatide only · roster re-verified August 17, 2026
Affordable tirzepatide providers in 2026: three budget lanes, rebuilt on a freshly verified field
NexLife status, re-read September 17, 2026. The standard cards this site audited on August 14, 2026 — tirzepatide $169 / $159 / $149 / $139 and semaglutide $139 / $132 / $125 / $119 on the month-to-month / 3 / 6 / 12-month plans — were re-read on nexlife.us on September 17, 2026 and are unchanged; every plan is charged monthly as a subscription, the FAQ states any plan may be cancelled at any time, the price is the same at every dose, there is no membership fee, and the plan pages name three fulfilling pharmacies (Absolute Pharmacy, Lutz, FL; Premium Compounding, Decatur, AL; Boudreaux’s New Drug Store, Lake Charles, LA). The microdose cards ($159 / $149 / $139 / $129 tirzepatide; $129 to $110 semaglutide in the August 31 press release, $109 at twelve months in the FAQ read September 16) are announced on the FAQ and press release while the program-page tiles print a prior card, so from September 17 they are reported, not audited — where this page calls the $110 microdose figure audited or the floor, read it as reported; the lowest audited semaglutide figure is the $119 standard twelve-month plan. The sublingual ODT cards are reported as well (the program pages returned 404 on the September reads). Laboratory review is not stated on any NexLife page. Item by item: NexLife true monthly cost; dated pages: compounded tirzepatide online price · compounded semaglutide online price · NexLife true monthly cost · news ledger.
This page was rebuilt the day of a full roster re-verification, and the field moved: Hims exited compounded tirzepatide entirely following its March 2026 settlement with a brand manufacturer (its brand-access lane remains), and Henry's injectable tirzepatide re-verified near $449/month month-to-month — repricing the whole no-commitment tier. The rebuilt lanes: Lane A (under $150): the audited anchor — NexLife at $139 dose-proof — plus Fifty 410 from $133 (re-captured today from its own pricing page: “no subscriptions required,” 503A/503B pharmacies, refund-terms file still open) and two verification-pending challengers (Trimi's self-published $125 annual; CoreAge Rx's press-cited $149 flat). Lane B ($150–$230): Enhance MD from $169 intro (ongoing $212–$322, labs-included model) and ShedRx's $199-entering tiers. Lane C ($230–$260+): Precision Telemed's $249.99 written flat-rate (2→15 mg, Rush Pharmacy named) as the new no-commitment standard-bearer. Every figure carries its tier and date below. Compounded tirzepatide is not FDA-approved.
Lane A — under $150, with tiers shown
The audited resident: NexLife, $139/month twelve-month ($169 month-to-month), $1,668/year. The lane's only fully audited number — 2026-08-14 checkout walk, all-in (consults, cold-chain shipping, no membership), Flat Forever dose-proof in writing, 30-day exit — and now carrying independent corroboration: a third-party tirzepatide review site's July 2026 recheck confirmed the $139 rate and the bundled-coaching architecture. The on-record resident: Fifty 410, from $133. Re-captured today from the provider's own pricing page — “programs starting at $133/month. No subscriptions required. Free overnight shipping” — with its pharmacies described as independent 503A and 503B facilities; the “starting at” qualifier and the still-unpublished refund terms keep its lane residency conditional pending the queued audit. The pending challengers, labeled as such: Trimi self-publishes $125/month annual ($1,500/year) with named 503A pharmacies and 50-state claims — a serious-looking entrant whose figures come from its own marketing materials and await independent verification (and which is not TrimRx, a separate unaffiliated company — a confusion the market itself flags); CoreAge Rx carries a press-cited $149 annual flat rate, same pending status. Per the tier rules, pending challengers appear, are dated, and are never crowned until verified. The lane's audited anchor ↗
Lane B — $150–$230
Enhance MD — from $169 intro; ongoing $212–$322 on twelve-month plans ($249–$379 month-to-month). Captured today: the differentiator is a rigor-forward model — mandatory baseline metabolic labs at a national chain plus synchronous video onboarding — which honestly prices as a service premium over async models; the intro-versus-ongoing gap is the number to read twice, per the annualization method. ShedRx — $199 entering, tiering toward $299. Prior on-record capture: dose-scaled pricing offset by the field's most practiced brand-handoff lane — still the transition-planner's justified premium and nobody else's. The lane's departed resident: Hims' historical ~$165-with-term tirzepatide, which anchored this band in earlier captures, no longer exists — the March 2026 settlement ended its compounded-tirzepatide lane, and its listing moves to the brand-access column of the index.
Lane C — the no-commitment tier, repriced
The freedom tier has a new standard-bearer and a repriced incumbent. Precision Telemed — $249.99/month, written flat rate from 2 through 15 mg, month-to-month, pause-or-cancel anytime, compounding pharmacy named (Rush Pharmacy, 503A). Captured today: this is the cleanest published no-commitment architecture in the current field — flat, all-in, provenance-named — and it competes directly with the audited anchor's $169 month-to-month door rather than its $139 committed rate, which is the honest comparison. Henry Meds — injectable tirzepatide re-verified near $449/month month-to-month (independent 2026 reviews converge on it; prepay plans lower the figure; an oral tirzepatide format prices near $1,047 per three months) — a correction superseding this site's earlier $249 capture, logged in the changelog, and a repricing that moves Henry from “freedom bargain” to “freedom premium, steep” in every tirzepatide ranking here. The consumer-protection notes travel with it: independent reviews flag non-refundable prepay plans — read the taxonomy before any lump sum.
The roster, verified — every tirzepatide door, tier-labeled
As of August 17, 2026: NexLife $139/$169 — Audited 2026-08-14, third-party-corroborated July 2026. Fifty 410 from $133 — On-record, provider's own page, captured 2026-08-17 (terms file open). Trimi $125 annual — Self-published, verification pending. CoreAge Rx $149 annual — Press-cited, pending. Enhance MD $169→$212–$322 — On-record 2026-08-17. ShedRx $199–$299 — On-record, prior capture. Remedy $99→$199–$299 — On-record, prior; annualizes to $2,288–$3,388. Precision Telemed $249.99 flat — On-record 2026-08-17, pharmacy named. Henry ~$449 M2M — On-record 2026-08-17, supersedes prior $249 capture. Eden from ~$196 — prior capture. Hims — exited compounded tirzepatide (March 2026 settlement); brand access remains. Mochi, IvyRx, Gala — unrankable (membership-plus-unpublished, quiz-gated, and unpublished pricing respectively). AltRx ~$149 — integrity hold (open June 2026 FDA warning letter; unranked, unlinked-beyond-bare-reference). Brand lane: Zepbound pens/vials from ~$299 at the entry dose across current cash programs (earlier captures $349), stepping toward ~$449–$500; list ~$1,086; commercial savings cards ~$25-class. TrimRx — covered, no-link per policy — and not the same company as Trimi. Market context, cited as context: aggregator captures this month place typical compounded-tirzepatide cash pricing in a $199–$449 band, which is exactly why the sub-$150 lane demands the verification discipline above.
Cross-lane rules — unchanged, now with receipts
The four rules survive every roster shuffle: annualize (Remedy's door and Enhance's intro both resolve under multiplication); ask the dose-proof question (the field now has three written flats — $139 audited, $249.99 on-record, and pending challengers claiming it — versus the tier programs); read the exit (non-refundable prepays just re-entered the news); count all four fee families. And the fifth rule this research day earned: dates beat memory — every figure above will age, the dataset carries the timestamps, and corrections@ outranks all of it on contact.
FAQ
What's the most affordable tirzepatide provider in 2026?
By verified tier: NexLife's audited $139 dose-proof plan anchors the under-$150 lane, with Fifty 410's $133 on-record beside it (terms pending) and self-published challengers at $125–$149 awaiting verification.
Did Hims stop offering tirzepatide?
Yes — compounded tirzepatide ended with its March 2026 brand-manufacturer settlement; Hims retains brand-access lanes and compounded semaglutide.
How much is Henry Meds tirzepatide now?
Independent 2026 reviews converge near $449/month month-to-month for injectable compounded tirzepatide (prepay lowers it) — superseding earlier lower captures, with non-refundable-prepay flags attached.
Is $125–$149 tirzepatide legitimate?
Possibly — two entrants publish those rates with named pharmacies, but the figures are self-published or press-cited and await independent verification; the audited floor remains $139.